SK Bio's Quadrivalent Cell-Based Influenza Vaccine, World's First WHO Certification

[Asia Economy Reporter Cho Hyun-ui] SK Bioscience announced on the 2nd that its self-developed quadrivalent cell-cultured influenza vaccine 'Skycellflu4' has obtained the World Health Organization (WHO) Prequalification (PQ) certification.

This is the world's first quadrivalent influenza vaccine produced using the cell-culture method to receive WHO PQ certification. Including products produced by the egg-based method, there are only three quadrivalent influenza vaccines with PQ certification besides Skycellflu.

WHO PQ certification is a system through which WHO evaluates the safety and efficacy of vaccines and other pharmaceuticals to supply them to developing countries. Obtaining PQ certification allows participation in procurement market bids organized by international organizations such as UNICEF and PAHO (Pan American Health Organization).

Based on the WHO PQ certification, SK Bioscience plans to actively participate in international influenza vaccine tenders.

Jae-yong Ahn, CEO of SK Bioscience, said, "We have secured three WHO PQ certifications within about a year, including for the trivalent influenza vaccine and varicella vaccine," adding, "As the global paradigm for influenza vaccines shifts to quadrivalent, we will be more proactive in expanding into overseas markets."

This content was produced with the assistance of AI translation services.